

---

## Safety Assessment of Hydroxyacetophenone as Used in Cosmetics

---

Status: Tentative Report for Public Comment  
Release Date: March 30, 2022  
Panel Meeting Date: June 16-17, 2022

*All interested persons are provided 60 days from the above release date (i.e., May 29, 2022) to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to the Cosmetic Ingredient Review (CIR) will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth.*

The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; David E. Cohen, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Preethi Raj, Senior Scientific Analyst/Writer, CIR.

## ABBREVIATIONS

CAS	Chemical Abstracts Service
CII	cumulative irritation index
CIR	Cosmetic Ingredient Review
Council	Personal Care Products Council
CPSC	Consumer Product Safety Commission
<i>Dictionary</i>	<i>International Cosmetic Ingredient Dictionary and Handbook</i>
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethyl sulfoxide
ECHA	European Chemicals Agency
EPA	Environmental Protection Agency
FCA	Freund's complete adjuvant
FDA	Food and Drug Administration
FEMA	Flavor and Extract Manufacturing Association
GRAS	generally recognized as safe
HRIPT	human repeat insult patch test
ICDRG	International Contact Dermatitis Research Group
JECFA	Joint FAO/WHO Expert Committee on Food Additives
LD	lethal dose
MMAD	mass median aerodynamic diameter
MeOH	methanol
MW	molecular weight
N/A	not applicable
NOAEL	no-observed-adverse-effect-level
NOEL	no-observed-effect-level
NR	not reported/none reported
OECD	Organisation for Economic Co-operation and Development
Panel	Expert Panel for Cosmetic Ingredient Safety
PDII	primary dermal irritation index
PII	primary irritation index
SIOPT	single insult occlusive patch test
SLS	sodium lauryl sulfate
TG	test guideline
THF	tetrahydrofuran
US	United States
VCRP	Voluntary Cosmetic Registration Program

## **ABSTRACT**

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of Hydroxyacetophenone as used in cosmetic formulations. This ingredient is reported to function in cosmetics as an antioxidant and skin-conditioning agent. The Panel reviewed relevant data related to the safety of this ingredient in cosmetic formulations, and concluded that Hydroxyacetophenone is safe in cosmetics in the present practices of use and concentration described in this safety assessment.

## **INTRODUCTION**

This assessment reviews the safety of Hydroxyacetophenone as used in cosmetic formulations. According to the web-based *International Cosmetic Ingredient Dictionary and Handbook* (wINCI; *Dictionary*), this ingredient is reported to function in cosmetics as an antioxidant and skin-conditioning agent - miscellaneous.<sup>1</sup>


This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that the Expert Panel for Cosmetic Ingredient Safety (Panel) typically evaluates, is provided on the Cosmetic Ingredient Review (CIR) website (<https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites>; <https://www.cir-safety.org/supplementaldoc/cir-report-format-outline>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Much of the data included in this safety assessment were found on the European Chemicals Agency (ECHA) website.<sup>2</sup> Please note that the ECHA website provides summaries of information generated by industry, and it is those summary data that are reported in this safety assessment when ECHA is cited.

## **CHEMISTRY**

### **Definition and Structure**

Hydroxyacetophenone (CAS No. 99-93-4) is the organic compound that conforms to the structure depicted in Figure 1.



**Figure 1.** Hydroxyacetophenone

### **Chemical Properties**

Hydroxyacetophenone has a molecular weight (MW) of 136.15 g/mol and an estimated log  $K_{ow}$  of 1.65.<sup>2,3</sup> The chemical properties of Hydroxyacetophenone are further outlined in Table 1.

### **Natural Occurrence**

Hydroxyacetophenone, also known as piceol, and its glucoside, picein, have been found at concentrations of 0.4% - 1.1% and 1.8 - 2.2%, dry weight, respectively, in Norway spruce (*Picea abies*) needles.<sup>4</sup>

### **Method of Manufacture**

According to a supplier, Hydroxyacetophenone is manufactured by first combining phenol and acetic anhydride to produce phenylacetate.<sup>5</sup> The phenylacetate is then converted to Hydroxyacetophenone via a Fries rearrangement, after which it is purified.

### **Impurities**

According to a supplier-provided certificate of analysis, gas liquid chromatography of a Hydroxyacetophenone sample confirmed up to 100% purity.<sup>6</sup> The chromatography results also indicate that the sample contained < 10 mg/kg phenol/1,2dichlorobenzene.

## **USE**

### **Cosmetic**

The safety of the cosmetic ingredient addressed in this assessment is evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of this ingredient in cosmetics. Use

frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in the FDA Voluntary Cosmetic Registration Program (VCRP) database. The cosmetic product categories named in the VCRP database indicate the intended uses of cosmetic ingredients, and are identified in 21 CFR Part 720. Data are submitted by the cosmetic industry in response to a survey conducted by the Personal Care Products Council (Council) of maximum reported use concentrations, also by product category. Neither the categories provided by the VCRP, nor those provided by the Council survey, include a designation for use via airbrush application. Airbrush devices, alone, are within the purview of the US Consumer Product Safety Commission (CPSC), while ingredients used in airbrush devices are within the jurisdiction of the FDA. As airbrush technology use for cosmetics has neither been evaluated by the CPSC, nor the use of cosmetic ingredients in airbrush technology by the FDA, no US regulatory authority has evaluated the safety of this delivery methodology for cosmetic ingredients. Moreover, no consumer habits and practices data are available to evaluate the risks associated with this use type.

According to 2022 VCRP survey data, Hydroxyacetophenone is reported to be used in 791 formulations, of which 671 are leave-on products; there are 236 reported uses in moisturizing products and 202 reported uses in face and neck products (Table 2).<sup>7</sup> Results from the 2020 concentration of use survey conducted by the Council indicate that the highest concentration of use reported for Hydroxyacetophenone is 5%, in non-spray night products, in paste masks, and in mud packs; the night product use represents the greatest maximum concentration of use for leave-on dermal exposure.<sup>8</sup>

This ingredient has been reported to be used in products that may come into contact with the eyes; for example, Hydroxyacetophenone is reported to be used at up to 0.23% in eye lotions and eye makeup removers. Reported use of Hydroxyacetophenone in lipsticks also indicates the possibility for incidental ingestion. Hydroxyacetophenone is also reported to be used at up to 0.6% in formulations that could come in contact with mucous membranes, such as bath soaps and detergents. Hydroxyacetophenone is reported to be used in 7 baby products; concentration of use data were not provided for this type of exposure.

Hydroxyacetophenone is reported to be used in cosmetic formulations that could be incidentally inhaled. For example, it is reported to be used in aerosol hair sprays (at up to 0.5%) and in moisturizing spray (at up to 0.3%), and in face powders (concentration of use not reported). In practice, as stated in the Panel's respiratory exposure resource document (<https://www.cir-safety.org/cir-findings>), most droplets/ particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and tracheobronchial regions of the respiratory tract and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount. Conservative estimates of inhalation exposures to respirable particles during the use of loose powder cosmetic products are 400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.

Additionally, although products containing this ingredient may be marketed for use with airbrush technology, this information is not available from the VCRP or the Council survey. Without information regarding the frequency and concentrations of use of these ingredients (and without consumer habits and practices data related to this use technology), the data are insufficient to evaluate the safety thereof in airbrush applications.

Hydroxyacetophenone is not restricted from use in any way under the rules governing cosmetic products in the European Union.<sup>9</sup>

### **Non-Cosmetic**

In 2011, the Joint Expert Committee on Food Additives (JECFA) mentioned Hydroxyacetophenone as a flavoring agent, and that it posed no safety concerns.<sup>10</sup> In Europe, Hydroxyacetophenone dietary exposure was estimated as 0.0002 µg/kg bw/d, while in Japan, Hydroxyacetophenone dietary exposure was estimated as 0.0059 µg/kg bw/d. Hydroxyacetophenone also has a Flavoring, Extract, and Manufacturing Association (FEMA) generally recognized as safe (GRAS) designation, under FEMA No. 4330.<sup>11</sup>

## **TOXICOKINETIC STUDIES**

Toxicokinetics studies were not found in the published literature, and unpublished data were not submitted

## **TOXICOLOGICAL STUDIES**

### **Acute Toxicity Studies**

#### **Dermal**

The acute dermal toxicity of Hydroxyacetophenone (99.97% pure) was investigated following a single, occlusive application to New Zealand white rabbits.<sup>2</sup> Five male and 5 female New Zealand white rabbits (no controls used) were exposed to a single, undiluted dose of 2000 mg/kg Hydroxyacetophenone for 24 h, and were observed for mortality and clinical abnormalities for 14 d. No animals died during the observation period. All animals exhibited abnormal stools, ocular discharge, erythema, and edema at the test site; by day 13, all external abnormalities had resolved. Upon necropsy, no visible lesions were observed. The acute dermal LD<sub>50</sub> in rabbits was > 2000 mg/kg bw.

## **Oral**

The acute oral toxicity of Hydroxyacetophenone (99.97% pure) was determined in groups of 5 male and 5 female Sprague-Dawley rats using a single gavage exposure of 0, 1000, 2000, or 5000 mg/kg Hydroxyacetophenone, in corn oil.<sup>2</sup> The animals were observed for 14 d prior to necropsy. No animals in the control and 1000 mg/kg group died, while 3 male and 3 female rats from the 2000 mg/kg group and 4 male and all 5 female rats from the 5000 mg/kg group died; all animals died within 24 h of exposure. During the 14-d observation period, 8 of the 5000 mg/kg group animals, all 10 of the 2000 mg/kg group animals, and 8 of the 1000 mg/kg group animals exhibited one of the following: oral discharge, nasal discharge, ocular discharge, alopecia, abnormal respiration, tremors, abnormal stools, lethargy, and/or moribundity. Two of the control animals exhibited abnormal stools on day 0 while 1 animal exhibited a stained coat on day 3-9 of the observation period. Upon post-mortem examination, fluid was found in either the stomach, duodenum, jejunum, and/or ileum. The acute oral LD<sub>50</sub> was determined to be 2240 mg/kg bw.

## **Short-Term Toxicity Studies**

### **Oral**

In a 28-d oral toxicity study, Hydroxyacetophenone (99.8% pure) was administered in propylene glycol, once daily by gavage, to groups of 5 male and 5 female Crl:WI(Han) rats at doses of 0, 40, 150, or 600 mg/kg bw, in accordance with Organisation for Economic Cooperation and Development (OECD) test guideline (TG) 407.<sup>2</sup> No substance-related mortality or changes in body weight gain occurred during the study period. No toxicologically significant changes were noted in hematology, clinical pathology, or organ weights, or upon gross and microscopic examination. The no-observed-adverse-effect-level (NOAEL) of Hydroxyacetophenone in rats was determined to be 600 mg/kg bw/d.

### **Inhalation**

In an inhalation toxicity study, 10 male Sprague-Dawley rats and concurrent controls (number not specified) were exposed, whole body, 6 h/d and 5 d/wk for 4 wk, to a dust concentration of 42 mg/m<sup>3</sup> Hydroxyacetophenone (99.7% pure).<sup>2</sup> No mortality occurred during observation. The average mass median aerodynamic diameter (MMAD) was measured as 11 µm, with a standard deviation of 2.0 µm. More than 48% of the detected particles were found to be ≤ 10 µm. A statistically significant decrease in albumin was observed after the first week of exposure, however these values returned to normal levels by the fourth week. The no-observed-adverse-effect-concentration (NOAEC) for inhalation toxicity in rats was determined to be 42 mg/m<sup>3</sup>.

## **Subchronic Toxicity Studies**

### **Oral**

Groups of 20 male and 20 female Sprague-Dawley rats were dosed with 0, 5, 15, or 45 mg/kg Hydroxyacetophenone (100% pure), in corn oil, via gavage, in accordance with OECD TG 408, for 90 d.<sup>2</sup> One mid-dose female was sacrificed moribund on day 57, 1 control male was found dead on day 12, and mortality in 7 animals distributed across the groups was considered due to accidental deaths. Several (1-3) male animals from the control and most treated groups exhibited chromodacryorrhea or lacrimation, which were not considered treatment-related. No treatment-related effects were seen upon body weight, ophthalmoscopic examination, urinalysis data, and pathology. Mean food consumption was slightly elevated in males from the 45 mg/kg group during the last 4 wk, but these increases were generally not dose-related and therefore were not considered toxicologically significant. A month and a half into the study, a dose-related increase in reticulocytes was seen in males and females (groups not specified), which was not statistically significant. The NOAEL for Hydroxyacetophenone in rats was determined to be 45 mg/kg bw/d.

## **DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES**

### **Oral**

Groups of 5 male and 5 female Crl: WI (Han) rats were dosed with 0, 40, 150, or 600 mg/kg bw/d Hydroxyacetophenone, in propylene glycol, via gavage, in accordance with OECD TG 422.<sup>2</sup> Males were exposed for 30 d, including 2 wk prior to mating, up to the day before necropsy; females were exposed from 2 wk prior to mating up to at least 4 d of lactation, for a total of up to 46 d. Males were killed and examined shortly after mating, while females and pups were killed and examined after day 4 of lactation. One female in the 600 mg/kg group experienced total litter loss after delivery and was killed after 24 h; since other litters of the same group were comprised of live offspring, this finding was not considered toxicologically significant. No toxicologically significant changes or differences in fetal or pup body weights, viability, litter size, sex ratios, maturation, gross pathology, or developmental parameters were observed for any group. The NOAEL was determined to be 600 mg/kg bw/d for both males and females in the parental generation, as well as the F<sub>1</sub> generation.

## **GENOTOXICITY STUDIES**

Details of the genotoxicity studies summarized below are described in Table 3.

Hydroxyacetophenone was not genotoxic in 3 separate bacterial reverse mutation assays, with concentrations ranging from 3 µmol/plate to 10,000 µg/plate.<sup>2</sup> In two gene mutation assays with L5178Y mouse lymphoma cells treated with concentrations of up to 1400 µg/ml Hydroxyacetophenone in the absence and presence of metabolic activation, diminished

cell growth rate and increased mutant frequencies were observed only at very high toxicities, and, specifically, in the absence of metabolic activation for one study.<sup>2</sup> Hydroxyacetophenone was not genotoxic at concentrations of up to 157 µg/ml in Chinese hamster ovary cell lines, with or without metabolic activation, in a sister chromatid exchange assay.<sup>2</sup> Groups of 5 male and 5 female ICR mice dosed via i.p. injection with up to 450 mg/kg Hydroxyacetophenone in a micronucleus assay exhibited minimal clinical abnormalities, and 1 male from the 450 mg/kg group died on the third day following exposure; no significant increase in micronucleated polychromatic erythrocytes was noted in either sex at any dose.<sup>2</sup>

### **CARCINOGENICITY STUDIES**

Carcinogenicity studies were not found in the published literature, and unpublished data were not submitted.

### **OTHER RELEVANT STUDIES**

#### **Tumor Promotion**

The effect of Hydroxyacetophenone upon cells later treated with chemical carcinogens (not identified) was evaluated in an in vitro cell transformation assay.<sup>2</sup> BALB/C-3T3 cells were treated with concentrations of 62.5, 250, 400, 700, or 1125 mg/ml Hydroxyacetophenone and tested for abnormalities in vitro and for tumor growth when injected in immunosuppressed, syngeneic animals. Appropriate negative (solvent control and untreated cells) and positive controls (2.5 µg/ml of 3-methylcholanthrene) were used and gave expected results. The BALB/C-3T3 cells did not produce neoplastic tumors in the animals. No significant increase in the frequency of transformed foci was observed, corresponding to 19-114% cell survival for cultures treated with the lowest and highest concentration of Hydroxyacetophenone. Thus, the test article was considered inactive at effecting tumor promotion in the transformation assay.

### **DERMAL IRRITATION AND SENSITIZATION STUDIES**

The dermal irritation and sensitization studies summarized below are described in Table 4.

Slight dermal irritation, including minimal erythema, without edema, was reported for 3 of 4 New Zealand white rabbits tested with a single, occlusive, 6 cm<sup>2</sup>, application of 0.5 g Hydroxyacetophenone.<sup>12</sup> In a similar irritation study, a 4-h, 1 in<sup>2</sup> occlusive application of 0.5 g of Hydroxyacetophenone was not irritating to the skin of 6 New Zealand white rabbits.<sup>2</sup> Groups of 6 New Zealand white rabbits were exposed to 0.5 ml of Hydroxyacetophenone at 3%, 5%, 15%, and 30% in 4 different vehicles: tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), methanol (MeOH), or *N,N*-dimethylformamide (DMF); which were also tested for irritation potential in the absence of the test article), for 4 h.<sup>2</sup> Hydroxyacetophenone in THF produced the maximum mean Draize score of 7.5 at the 3% concentration, and 5.5 at the 30% concentration (with average primary dermal irritation index (PDII) values of 6.8 and 5.1, respectively); the test article did not significantly increase the dermal irritancy of any vehicle. No edema or erythema occurred when 1%, 10%, or 50% aqueous Hydroxyacetophenone was applied to the abraded and intact skin of New Zealand white rabbits (3/group), under occlusion.<sup>13</sup> In a Buehler test, performed in 19 Dunkin Hartley guinea pigs, 20% aqueous Hydroxyacetophenone was shown to be a non-sensitizer.<sup>14</sup> In a maximization test, male Hartley guinea pigs induced twice with 5% Hydroxyacetophenone in propylene glycol, and challenged with a topical application of 0.5 g of 75% in petrolatum for 24 h, were not sensitized.<sup>2</sup>

In a single insult occlusive test (SIOPT), application of an SPF cream containing 0.05% Hydroxyacetophenone, tested as supplied (amount not specified), was not irritating to 22 subjects.<sup>15</sup> In another SIOPT, an occlusive application of 0.2 ml Hydroxyacetophenone was not irritating to 53 subjects.<sup>16</sup> In a 21-d cumulative irritation test of 32 subjects, using an SPF 70 cream, containing 0.05% Hydroxyacetophenone, repetitive application of 0.05 ml of the test article exhibited negligible potential for irritation with a total irritation score of 86, a mean cumulative irritation score of 2.69, a mean daily irritation score of 0.18, and a cumulative irritation index (CII) of 0.06 (compared to 773, 24.16, 1.61, and 0.54 for positive controls).<sup>17</sup> An SPF cream containing 0.5% Hydroxyacetophenone was tested in an HRIPT in 103 subjects; the test article was deemed non-sensitizing.<sup>18</sup> According to summary details from an HRIPT of 104 subjects, a test article containing 5% (in glycerin) of 99% pure Hydroxyacetophenone was deemed not sensitizing; 1 subject presented with two, grade 0.5 skin reactions during induction.<sup>19</sup>

### **OCULAR IRRITATION STUDIES**

The ocular irritation studies summarized below are described in Table 5.

The eyes of 4 healthy New Zealand white rabbits were treated with 0.1 g of undiluted Hydroxyacetophenone for 24 h, after which they were either rinsed with saline or remained unrinsed, and were observed for up to 21 d.<sup>2</sup> A Draize score of 63, out of a maximum score of 110, was recorded for the animal with the unrinsed eye, 48 h after treatment; this score is categorized as a severe irritant. The mean Draize score calculated for the 3 animals with rinsed eyes was 22, categorizing the test article as a moderate irritant. In another study, corneal opacity, severe ulceration, and mild iritis were observed in the eyes of 4 healthy New Zealand white rabbits treated with 0.1 ml of finely ground Hydroxyacetophenone by Draize method.<sup>12</sup> Three of the 4 treated eyes were free of corneal effects 7 d after treatment; moderate redness and chemosis persisted through

day 7 for all 4 test animals. Hydroxyacetophenone was considered a severe eye irritant to rabbit eyes under these study conditions.

## **CLINICAL STUDIES**

### **Case Reports**

A 79-yr-old man experienced dermatitis for 7 mo on the right upper and lower eye lid with the use of prescription eyedrops (not containing Hydroxyacetophenone) and a facial cream containing Hydroxyacetophenone (concentration in cream not provided).<sup>20</sup> In spite of the eyedrop prescription being changed several times, these lesions did not subside. A 2-d patch test was conducted on the back, with allergens found in the Spanish baseline series, Chemotechnique fragrance series, all previously used eye drops, and the facial cream. All patch test results were negative on day 2 and 4, except for a ?+ reaction to the face cream. Results from a repeated open application test conducted on the upper arm with the facial cream showed erythema, infiltration, and papules. Further patch tests conducted on manufacturer-supplied, individual ingredients in the face cream, revealed positive reactions only to 0.6% aqueous Hydroxyacetophenone (+ on day 2 and ++ on day 4). Furthermore, eczematous lesions resolved within 5- d use of tacrolimus, and lesions did not develop after discontinued use of the face cream. Patch test results for Hydroxyacetophenone in 10 controls were all negative.

### **SUMMARY**

The safety of Hydroxyacetophenone, as used in cosmetics, is reviewed in this safety assessment. According to the *Dictionary*, Hydroxyacetophenone is reported to function as an antioxidant and skin-conditioning agent.

According to 2022 VCRP data, the Hydroxyacetophenone is reported to be used in 791 formulations, of which the two highest number of reported leave-on uses are 236 in moisturizing products and 202 in face and neck products. Concentration of use survey data from a 2020 survey indicate that the highest reported maximum concentration of use for Hydroxyacetophenone is at up to 5% in non-spray night products, in paste masks, and mud packs.

The acute dermal LD<sub>50</sub> of Hydroxyacetophenone was > 2000 mg/kg bw in New Zealand white rabbits. Groups of 5 Sprague-Dawley rats were administered a single oral dose of up to 5000 mg/kg Hydroxyacetophenone, in corn oil, via gavage. Three male and 3 female rats from the 2000 mg/kg group, and 4 male and 5 female rats from the 5000 mg/kg group died within 24 h. During the 14-d observation period, 8 animals from the 5000 mg/kg group, all 10 in the 2000 mg/kg group, and 8 from the 1000 mg/kg group exhibited either oral discharge, nasal discharge, ocular discharge, alopecia, abnormal respiration, tremors, abnormal stools, lethargy, and/or moribundity; 2 control animals exhibited abnormal stools on day 0. The acute oral LD<sub>50</sub> of Hydroxyacetophenone was determined to be 2240 mg/kg bw.

In a 28-d oral toxicity study, no toxicologically significant findings were noted in rats administered up to 600 mg/kg bw Hydroxyacetophenone; the NOAEL was determined to be 600 mg/kg bw/d. In an inhalation study, no mortality occurred in rats exposed, whole body, 6 h/d and 5 d/wk, for 4 wk, with 42 mg/m<sup>3</sup> Hydroxyacetophenone; a statistically significant decrease in albumin after the first week of exposure returned to normal levels by the fourth week. The NOAEC for inhalation toxicity in rats was, therefore, determined to be 42 mg/m<sup>3</sup>.

Groups of 20 male and 20 female Sprague-Dawley rats were dosed with up to 45 mg/kg Hydroxyacetophenone, in corn oil, via gavage, for 90 d. One control male was found dead on day 12, and mortality in 7 animals across the dose groups (number not specified) was considered accidental deaths. Dose-related increases in the mean food consumption of males in the 45 mg/kg group and the reticulocytes in male and females (groups not specified) were not statistically significant. The NOAEL for Hydroxyacetophenone in rats was determined to be 45 mg/kg bw/d.

In an oral reproductive and developmental toxicity study, performed in accordance with OECD TG 422, groups of 5 male and 5 female CrI: WI (Han) rats were dosed with 0, 40, 150, or 600 mg/kg bw/d Hydroxyacetophenone, in propylene glycol, via gavage, for up to 46 d. One dam in the 600 mg/kg group experienced total litter loss; however, because other litters of the same group were comprised of live offspring, this finding was not considered toxicologically significant. No toxicologically significant changes or differences in fetal developmental parameters were seen and the NOAEL was determined to be 600 mg/kg bw/d Hydroxyacetophenone for both males and females in the parental, as well as the filial, generation.

Hydroxyacetophenone was not genotoxic in 3 separate bacterial reverse mutation assays, at concentrations of up to 10,000 µg/plate, in the presence or absence of metabolic activation. In 2 gene mutation assays, L5178Y mouse lymphoma cells treated at concentrations of up to 1400 µg/ml Hydroxyacetophenone, in the presence or absence of metabolic activation, exhibited a diminished cell growth rate and increase in mutant frequencies only at very high toxicities, and specifically, in the absence of metabolic activation for one study. Hydroxyacetophenone was not genotoxic in a sister chromatid exchange assay, in which Chinese hamster ovary cell lines were treated with concentrations of up to 157 µg/ml. A significant increase of micronucleated polychromatic erythrocytes was not observed in ICR mice administered up to 450 mg/kg Hydroxyacetophenone, via i.p. injection.

BALB/C-3T3 cells were tested with Hydroxyacetophenone, at concentrations of up to 1125 mg/ml, and subsequently treated with unidentified chemical carcinogens in an in vitro cell transformation assay. Hydroxyacetophenone was considered inactive at effecting tumor promotion.

Slight dermal irritation was reported for 3 of 4 New Zealand white rabbits treated with an occlusive, 6 cm<sup>2</sup> patch of 0.5 g Hydroxyacetophenone, moistened with saline, for 4 h. In a similar study, 0.5 g of Hydroxyacetophenone applied to rabbit skin in a 1 in<sup>2</sup>, occlusive patch for 4 h, did not cause dermal irritation to control or treated sites. In a study comparing the dermal irritation potential of THF, DMSO, MeOH, or DMF, individually, and when 0.5 ml Hydroxyacetophenone was added to each, the test article did not increase the irritancy of any vehicle. Guinea pigs were not sensitized to 20% aqueous Hydroxyacetophenone in a Buehler test. In a maximization test, no sensitization occurred when male Hartley guinea pigs were induced twice with 5% Hydroxyacetophenone, in propylene glycol, and challenged with a topical application 0.5 g of 75% Hydroxyacetophenone in petrolatum for 24 h.

Hydroxyacetophenone was not irritating in 2 separate SIOPTs, either at 0.05% in an SPF product tested in 22 subjects, or at a dose of 0.2 ml, tested in 53 subjects. In a 21-d cumulative irritation test, a SPF cream, containing 0.05% Hydroxyacetophenone, was determined to have a negligible potential for irritation in 32 subjects, due to a total irritation score of 86, a mean cumulative irritation score of 2.69, and mean daily irritation score of 0.18, and a CII of 0.06. A SPF cream containing 0.5% Hydroxyacetophenone was found to be non-sensitizing in an HRIPT of 103 subjects. In spite of 1 subject presenting with 2, grade 0.5 reactions during induction, 5% Hydroxyacetophenone, in glycerin, was deemed a non-sensitizer in 104 subjects.

New Zealand white rabbit eyes treated with 0.1 g of undiluted Hydroxyacetophenone, unrinsed, produced a Draize score of 63, categorized as a severe irritant, while eyes rinsed with 0.9% saline for 30 sec produced a Draize score of 22, categorized as a moderate irritant. In another study, New Zealand white rabbit eyes treated with 0.1 ml, finely ground Hydroxyacetophenone showed signs of moderate to severe discharge, moderate chemosis, and moderate to severe redness when scored 24 h following treatment. Corneal effects dissipated in 3 of the 4 treated eyes within 7 d after treatment; moderate redness and chemosis persisted through day 7 for all treated eyes.

A 79- yr-old man presented with dermatitis for 7 mo on the right upper and lower eye lid with the use of prescription eyedrops and a facial cream containing Hydroxyacetophenone (concentration in cream not provided). Positive patch-test reactions occurred for 0.6% aqueous Hydroxyacetophenone, which resolved with use of tacrolimus and discontinuation of cream use.

## **DISCUSSION**

This assessment reviews the safety of Hydroxyacetophenone as used in cosmetic formulations. The Panel reviewed the available data and concluded that this ingredient is safe in cosmetics in the present practices of use and concentration described in the safety assessment.

The Panel noted that this ingredient has GRAS status as a flavoring agent, and was not a dermal irritant or sensitizer when tested at 5% (which is the maximum reported concentration of use) in a guinea pig maximization test or in a human repeated insult patch test. Additionally, the Panel considered that Hydroxyacetophenone has a favorable toxicological profile. Negative results from multiple genotoxicity studies and the lack of structural alerts mitigated the need for carcinogenicity data.

The Panel acknowledged the ocular irritation observed in 2 studies in rabbits, in light of use in products applied near the eye ( i.e., up to 0.23% in eye lotions and eye makeup removers). In both studies, irritation resulted from neat application, and in one study, from granular exposure. The Panel stated that manufacturers should be aware of the potential for ocular irritation when formulating products that contain this ingredient, for use near the eye, and that measures should be taken to ensure that these products are not irritating.

The Panel considered that Hydroxyacetophenone is reported to be used in baby products, without reported concentrations of use. Furthermore, the Panel discussed the maximum reported concentration of use for Hydroxyacetophenone, at up to 5% in non-spray night products, in paste masks, and in mud packs; the Panel reiterated their expectation that any unreported concentrations of use in baby products would not exceed the maximum reported use.

The Panel discussed the issue of incidental inhalation exposure from use in sprays (e.g., in a hair sprays at up to 0.5%) and in face powders (concentration of use not reported). The data available from a short-term inhalation study indicates little potential for respiratory effects at relevant doses. Furthermore, droplets/particles deposited in the nasopharyngeal or tracheobronchial regions of the respiratory tract present no toxicological concerns based on the chemical and biological properties of this ingredient. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. A detailed discussion and summary of the Panel's approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available at <https://www.cir-safety.org/cir-findings>.



## **CONCLUSION**

The Expert Panel for Cosmetic Ingredient Safety concluded that Hydroxyacetophenone is safe in cosmetics in the present practices of use and concentration described in this safety assessment.

## TABLES

**Table 1. Chemical properties of Hydroxyacetophenone**

Property	Value	Reference
Physical Form (@ 20 °C and 1013 hPa)	Solid	2
Color	White to beige	6
Molecular Weight (g/mol)	136.15	3
Specific Gravity (@ 20 °C)	1.27	2
Vapor pressure (mmHg @ 20 °C)	0.000015	2
Melting Point (°C @ 1013 hPa)	110	2
Water Solubility (g/l @ 22 °C)	10	2
log K <sub>ow</sub> (@ 25 °C)	1.35 (estimated)	2
Disassociation constants (pK <sub>a</sub> @ 25 °C)	8.05	2

**Table 2. Frequency (2022) and concentration (2020) of use of Hydroxyacetophenone**

	# of Uses <sup>7</sup>	Max Conc of Use (%) <sup>8</sup>
<b>Totals*</b>	<b>791</b>	<b>0.00009 - 5</b>
<b>Duration of Use</b>		
<i>Leave-On</i>	671	0.02 - 5
<i>Rinse-Off</i>	119	0.000099 - 5
<i>Diluted for (Bath) Use</i>	1	0.25
<b>Exposure Type</b>		
Eye Area	47	0.23
Incidental Ingestion	2	NR
Incidental Inhalation-Spray	4; 265 <sup>a</sup> ; 232 <sup>b</sup>	0.3 – 0.5; 0.5 <sup>a</sup>
Incidental Inhalation-Powder	3; 232 <sup>b</sup> ; 3 <sup>c</sup>	0.075 – 0.3 <sup>c</sup>
Dermal Contact	754	0.000099 - 5
Deodorant (underarm)	5 <sup>a</sup>	NR
Hair - Non-Coloring	33	0.02 – 0.5
Hair-Coloring	NR	NR
Nail	2	NR
Mucous Membrane	23	0.000099 – 0.6
Baby Products	7	NR

\*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

<sup>a</sup> It is possible these products are sprays, but it is not specified whether the reported uses are sprays.

<sup>b</sup> Not specified whether a spray or a powder, but it is possible the use can be as a spray or a powder, therefore the information is captured in both categories

<sup>c</sup> It is possible these products are powders, but it is not specified whether the reported uses are powders

NR – not reported

**Table 3. Genotoxicity studies**

Test Article	Concentration/Dose	Vehicle	Test System	Procedure	Results	Reference
<b>IN VITRO</b>						
Hydroxyacetophenone	3 µmol/plate, with and without metabolic activation	ethanol	<i>Salmonella typhimurium</i> strains TA 98, 100	Bacterial reverse mutation assay	Not genotoxic. Appropriate negative and positive control gave expected results.	<sup>21</sup>
Hydroxyacetophenone, 99.97% pure	Up to 5000 µg/plate, with and without metabolic activation	DMSO	<i>S. typhimurium</i> TA 98, 100, 1535, 1537, 1538	Bacterial reverse mutation assay	Not genotoxic. Appropriate negative and positive control gave expected results.	<sup>2</sup>
Hydroxyacetophenone	1.0 -10,000 µg/plate, with and without metabolic activation	DMSO	<i>S. typhimurium</i> strains TA 98, 100, 1535, 1537, 1538	Bacterial reverse mutation assay	Not genotoxic. Appropriate negative and positive controls gave expected results.	<sup>2</sup>
Hydroxyacetophenone, 99.97% pure	100- 1400 µg/ml without metabolic activation; 10-800 µg/ml with metabolic activation	DMSO	Mouse lymphoma L5178Y cells	Mammalian gene mutation assay	Clastogenic; the test article was positive for genotoxicity in the absence of exogenous metabolic activation, and the observed mutant frequencies roughly increased at the highest tested concentrations; genotoxicity was ambiguous in the presence of metabolic activation. Non-metabolically activated cultures treated with doses of 100-1400 µg/ml of the test article exhibited a growth rate of 103% to 34%, respectively, while activated cultures treated with concentrations of 10-800 µg/ml test article exhibited a growth rate of 76% to 13%, respectively. The non-activated portion of the study was repeated in order to obtain cultures with less than 34% growth rate; cloned cultures treated with 1570 to 1020 µg/ml of the test article exhibited growth rates from 8% to 72%. Four of these non-activated clone cultures, with growth rates > 10%, exhibited mutant frequencies at least twice the mean mutant frequency of solvent controls. A dose-dependent response was not noted in the treated cultures. An increase in the frequency of small colonies in treated cultures, compared to control cultures, was consistent with damage to multiple loci on chromosome 11 in addition to loss of the TK locus. Appropriate negative and positive controls gave expected results.	<sup>2</sup>
Hydroxyacetophenone	188-1250 µg/ml without metabolic activation; 31.5- 500 µg/ml	DMSO	Mouse lymphoma L5178Y cells	Mammalian gene mutation assay	Ambiguous genotoxicity; without metabolic activation, mutant cell frequencies were significantly increased only at very high toxicities (4.7 % relative growth). In the presence of metabolic activation, the test material was converted to more active form or forms. Treatments with 31.5 - 500 µg/ml test article when assayed produced mutant frequencies of 3.4- 5.6 fold, over a wide range of toxicities. Appropriate negative and positive controls gave expected results.	<sup>2</sup>
Hydroxyacetophenone	4.7-157 µg/ml without metabolic activation or 47-1570 µg/ml with metabolic activation	DMSO	Chinese hamster ovary cell line	Sister chromatid exchange assay	Not genotoxic. Appropriate negative and positive controls gave expected results.	<sup>2</sup>
<b>IN VIVO</b>						
Hydroxyacetophenone, > 99% pure	0,113,225,450 mg/kg	Corn oil	Groups of 5 male and 5 female ICR mice	Micronucleus assay. Animals were given a single intraperitoneal dose; cyclophosphamide was used for the positive controls.	Not genotoxic; clinical abnormalities after dosing included lethargy, rough hair coat, and hunched posture. One male from the 450 mg/kg group died on the third day after treatment. No significant increase in micronucleated polychromatic erythrocytes was noted in either sex or for any dosage. Appropriate negative and positive controls gave expected results.	<sup>2</sup>

DMSO – dimethyl sulfoxide

NR – not reported

**Table 4. Dermal irritation and sensitization studies**

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
<b>ANIMAL</b>					
<b>Irritation</b>					
Hydroxyacetophenone	0.5 g, moistened with saline	4 New Zealand white rabbits	A single, 6 cm <sup>2</sup> , occlusive application of the test article, moistened with saline, was made to clipped skin, for 4 h. Test sites were evaluated 72 h after patch removal, using the Draize scoring system.	Slight dermal irritation was reported for 3 of the 4 animals, including minimal erythema, without edema. (No further details provided).	<sup>12</sup>
Hydroxyacetophenone, 99.97% pure	0.5 g, moistened with sterile water	6 New Zealand white rabbits	A single, occlusive application of the test article, moistened with sterile water, was made neat to a shaved skin area of 1 in <sup>2</sup> for 4 h; an untreated skin site on the same animal was used as the control. The test sites were observed for up to 72 h.	All control and treated sites were free of dermal irritation throughout the study period.	<sup>2</sup>
Hydroxyacetophenone, 99.87% pure	0.5 ml, at 3%, 5%, 15%, 30% (in THF, DMSO, MeOH, or DMF); 0.5 ml	New Zealand white rabbits (6/group)	The test articles (0.5 ml) were applied under occlusion to a shaved area of 6 cm <sup>2</sup> for 4 h. An adjacent site on each treated animal was exposed to the respective vehicle (neat), and served as a vehicle control; an untreated site served as a negative control. After exposure, skin was wiped free of excess test material with an adsorbent pad and test sites were observed for up to 14 d. Test sites were evaluated for irritation using the Draize method, and all sites were scored 1, 24, 48, and 72 h after patch removal; test sites at which DMF and THF were used as the vehicle were observed at 7 d and up to 14 d, respectively. The maximum possible Draize score was 8.0. The primary dermal irritation index (PDII) was calculated using Draize scores recorded at 1, 24, 48, and 72 h after exposure.	After 72 h, THF was shown to be the most irritating vehicle, with a maximum mean Draize score of 7.5 (and average PDII of 6.5); Hydroxyacetophenone in THF produced maximum mean Draize scores of 7.5 at the 3% concentration, and 5.5 at the 30% concentration (with average PDII of 6.8 and 5.1, respectively). Lower scores were observed with the use of the other vehicles, and scores were comparable across the concentrations with each vehicle; at the 30% concentration, Hydroxyacetophenone in DMSO had a maximum mean Draize score of 1.2 (and average PDII of 0.3), in MeOH had a maximum mean Draize score of 0.7 (and average PDII of 0.2), and in DMF had a maximum mean Draize score of 0.3 (and average PDII of 0.1). Recovery times were > 14 d for THF, 7 d for DMF, and 3 d for DMSO and MeOH. The test article did not significantly increase the dermal irritancy of any vehicle.	<sup>2</sup>
Hydroxyacetophenone	1%, 10%, and 50% (aqueous)	New Zealand white rabbits (3/group)	Fur was removed from the test site 24 h prior to intended application; an occlusive application was made to both abraded and intact skin. Reactions were scored 24 and 72 h after application, averaged separately for erythema and edema, and then summed to arrive at the PII.	Not irritating; PII = 0 for all test concentrations	<sup>13</sup>
<b>Sensitization</b>					
Hydroxyacetophenone	20% w/v (aqueous)	Dunkin-Hartley guinea pigs (19 animals in the test group; 10 animals in the control group)	Delayed contact hypersensitivity test (Buehler test). Animals were patched with 20% aqueous test article at pH 5.3 (amount not specified) for both topical induction and challenge applications. (Specific details not provided). Readings for potential erythematous or sensitization reactions were taken 24 and 48 h after patch removal. Bodyweights were also monitored over the study duration of 4 wk.	Not sensitizing; all irritancy and severity scores were 0. One animal died during the test, but this death was not treatment-related. No significant body weight changes occurred.	<sup>14</sup>

**Table 4. Dermal irritation and sensitization studies**

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
Hydroxyacetophenone	5% during induction in propylene glycol; 75% during challenge in petrolatum	20 male Hartley guinea pigs	Guinea pig maximization test. An intradermal injection of 5% test article (in propylene glycol, with and without FCA) was made during induction. Eight days later, the animals were induced for a second time with a topical application of 5% Hydroxyacetophenone in propylene glycol. Two wk after the second induction, a topical challenge application was made with 0.5 g of 75% Hydroxyacetophenone in petrolatum for 24 h. Dinitrochlorobenzene was used as a positive control (number of controls not specified).	Not sensitizing	<sup>2</sup>
<b>HUMAN</b>					
<b>Irritation</b>					
SPF 50 cream containing 0.05% Hydroxyacetophenone	applied neat	22	SIOPT; the test article (amount not specified) was applied for 24 h. An SPF 70 gel cream product was used as the control.	Not irritating; PII of 0.0	<sup>15</sup>
Hydroxyacetophenone	0.2 ml	53	SIOPT; A single, occlusive application of the test material was applied to the back using a 0.75 in <sup>2</sup> patch for 48 h. Readings were performed 48 and 72 h after application.	Not irritating	<sup>16</sup>
SPF 70 cream containing 0.05% Hydroxyacetophenone	applied neat; 0.05 ml	32	21-d cumulative irritation test. The test article was used as supplied. Occlusive applications were made using a 15 mm Webril patch, and scored on a 5-pt ICDRG grading scale upon removal, 5 d/wk for 3 consecutive weeks; patches applied on Friday remained in place until Monday. One site was also treated with 0.05 ml of 0.25% SLS as a positive control, and a plain cotton patch was applied as a negative control.	Negligible potential for irritation; the test article produced a total irritation score of 86, a mean cumulative irritation score of 2.69, a mean daily irritation score of 0.18, and a CII of 0.06 (compared to 773, 24.16, 1.61, and 0.54, respectively, for the positive controls).	<sup>17</sup>
<b>Sensitization</b>					
SPF 70 cream containing 0.5% Hydroxyacetophenone	applied neat; 0.2 g (induction and challenge)	103	In an HRIPT, 24- h occlusive patches containing 0.2 g of the test material were applied 3x/wk, for 3 wk, for a total of 9 induction applications. After a 2-wk non-treatment period, a 24-h challenge application was made to a previously untreated site in the same manner as the induction applications, and reactions were scored at 24, 48, 72, and 96 h after application.	Not sensitizing	<sup>18</sup>
Hydroxyacetophenone, 99% pure	5% in glycerin	104	An HRIPT was conducted (no further details were provided).	Not sensitizing; 1 subject presented with two, grade 0.5 skin reactions during induction	<sup>19</sup>

**Abbreviations:** CII- cumulative irritation index; DMF- *N,N*-dimethylformamide; DMSO – dimethyl sulfoxide; FCA – Freund’s complete adjuvant; HRIPT- human repeat insult patch test; ICDRG- International Contact Dermatitis Research Group; MeOH – methanol; PDII – primary dermal irritancy index; PII – primary irritation index; SIOPT – single insult occlusive patch test; SLS- sodium lauryl sulfate; THF- tetrahydrofuran

**Table 5. Ocular irritation studies**

<b>Test Article</b>	<b>Concentration/Dose</b>	<b>Test Population</b>	<b>Procedure</b>	<b>Results</b>	<b>Reference</b>
Hydroxyacetophenone, 99.97% pure	0.1 g, undiluted	4 New Zealand white rabbits	The untreated eye of each animal served as the control, and both eyes were observed for up to 21 d after exposure. Potential for ocular irritancy was examined in the first animal leaving the treated eye unrinsed. In the remaining 3 animals, anesthetic was used prior to dosing, even for control eyes, and treated eyes were rinsed with approximately 120 ml of 0.9% saline, for 30 sec.	In the animal with the unrinsed eye, corneal opacity, conjunctival redness, iridial irritation, chemosis, and discharge were noted, all of which resolved by 21 d. A Draize score of 63, out of a maximum score of 110, was recorded for the unrinsed eye, 48 h after treatment; this score is categorized as a severe irritant. In the animals with rinsed treated eyes, milder conjunctival effects were seen, but resolved within 7 d; the mean Draize score calculated for the 3 animals with rinsed eyes was 22, categorizing the test article as a moderate irritant.	<sup>2</sup>
Hydroxyacetophenone	0.1 ml, finely ground	4 New Zealand white rabbits	The right eyes of the animals were treated with 0.1 ml Hydroxyacetophenone (duration not provided), and ocular lesions were scored approximately 24 h and 7 d following treatment by the Draize method.	The treated eyes showed signs of moderate to severe discharge, moderate chemosis (swelling) and moderate to severe redness at the 24 h observation. Corneal opacity, severe ulceration, and mild iritis was observed in all 4 treated eyes. Three of the 4 treated eyes were free of corneal effects 7 d after treatment; moderate redness and chemosis persisted through day 7 for all 4 test animals. Hydroxyacetophenone was considered a severe eye irritant to rabbit eyes under these study conditions.	<sup>12</sup>

## REFERENCES

1. Nikitakis J., Kowcz A. Web-based International Cosmetic Ingredient Dictionary and Handbook (wINCI Dictionary). <http://webdictionary.personalcarecouncil.org/jsp/IngredientSearchPage.jsp>. Last Updated 2020. Accessed November 23, 2020.
2. European Chemical Agency (ECHA). REACH registration dossier: 4'-hydroxyacetophenone (CAS 99-93-4). <https://echa.europa.eu/registration-dossier/-/registered-dossier/11354/1>. Last Updated 2020. Accessed 02/10/2021.
3. U.S. National Library of Medicine. PubChem : 4'-Hydroxyacetophenone (Compound). <https://pubchem.ncbi.nlm.nih.gov/compound/4-Hydroxyacetophenone#section=Food-Additives-and-Ingredients>. Last Updated 02/13/2021. Accessed 02/15/2021.
4. Metsämuuronen S, Sirén H. Bioactive phenolic compounds, metabolism and properties: a review on valuable chemical compounds in Scots pine and Norway spruce. *Phytochem Rev.* 2019;18(3):623-664.
5. Symrise. 2021. Production flow chart of SymSave®H (Hydroxyacetophenone). Unpublished data submitted by the Personal Care Products Council on June 22, 2021.
6. Symrise. 2021. Certificate of analysis SymSave®H (Hydroxyacetophenone). Unpublished data submitted by the Personal Care Products Council on June 22, 2021.
7. U.S. Food and Drug Administration Center for Food Safety & Applied Nutrition (CFSAN). 2022. Voluntary Cosmetic Registration Program - Frequency of Use of Cosmetic Ingredients (VCRP). Obtained under the Freedom of Information Act from CFSAN; requested as "Frequency of Use Data" January 4, 2022; received January 11, 2022.
8. Personal Care Products Council. 2021. Concentration of Use by FDA Product Category: Hydroxyacetophenone. Unpublished data submitted by Personal Care Products Council on January 25, 2021.
9. European Commission. CosIng database; following Cosmetic Regulation No. 1223/2009. <http://ec.europa.eu/growth/tools-databases/cosing/>. Last Updated 2016. Accessed 11/1/2019.
10. Joint FAO/WHO Expert Committee on Food Additives. Safety evaluation of certain food additives and contaminants: seventy-third report of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) Geneva, Switzerland 2011. [https://apps.who.int/iris/bitstream/handle/10665/44521/9789241660648\\_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/44521/9789241660648_eng.pdf?sequence=1).
11. Waddell WJ, Cohen SM, Feron VJ, et al. GRAS Flavoring Substances 23; The 23rd publication by the FEMA Expert Panel presents safety and usage data on 174 new generally recognized as safe flavoring ingredients. *Food Technology*. 22-49. <https://www.femaflavor.org/sites/default/files/23.%20GRAS%20Substances%20%284254-4429%29.pdf>. Accessed February 16, 2021.
12. Hoechst Celanese Corp. Acute skin and eye irritation in rabbits. U.S. Environmental Protection Agency (EPA); 1985. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0570600.xhtml>. Accessed January 29, 2021.
13. Life Science Research. 1977. Rabbit closed patch study Parahydroxyacetophenone. Unpublished data submitted by the Personal Care Products Council on June 21, 2021.
14. Life Science Research. 1977. Delayed contact hypersensitivity in guinea-pigs (Buehler test) Parahydroxyacetophenone. Unpublished data submitted by the Personal Care Products Council on June 21, 2021.
15. Anonymous. 2018. Human patch test SPF product containing 0.05% Hydroxyacetophenone. Unpublished data submitted by the Personal Care Products Council on May 3, 2021.
16. Symrise. 2021. Summary dermal irritation study SymSave®H (Hydroxyacetophenone). Unpublished data submitted by the Personal Care Products Council on June 22, 2021.
17. Anonymous. 2017. 21-Day cumulative irritation assay Sample: SPF 70 cream containing 0.05% Hydroxyacetophenone. Unpublished data submitted by the Personal Care Products Council on May 3, 2021.

18. Anonymous. 2017. Repeated insult patch test of an SPF 70 cream containing 0.5% Hydroxyacetophenone. Unpublished data submitted by the Personal Care Products Council on May 3, 2021.
19. Symrise. 2013. Summary of an HRIPT SymSave®H (Hydroxyacetophenone). Unpublished data submitted by the Personal Care Products Council on June 22, 2021.
20. Sanz-Sánchez T, Garrido R, Cid P, Díaz-Díaz R. Allergic contact dermatitis caused by hydroxyacetophenone in a face cream: Allergic face dermatitis caused by Hydroxyacetophenone. *Contact Dermatitis*. 2018;78:174-175.
21. Florin I, Rutberg L, Curvall M, Enzell C. Screening of tobacco smoke constituents for mutagenicity using the Ames test. *Toxicology*. 1980;15:219-232.